Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:31 pm Sale | 2025-09-30 | 13G | Nektar Therapeutics NKTR | Nantahala Capital Management, LLC | 418,522 2.200% | -291,239 (-41.03%) | Filing History |
| 2025-11-14 4:23 pm Sale | 2025-09-30 | 13G | Nektar Therapeutics NKTR | TCG Crossover GP II, LLC | 0 0.000% | -1,933,333 (Position Closed) | Filing History |
| 2025-11-13 5:45 pm Purchase | 2025-09-30 | 13G | Nektar Therapeutics NKTR | G1 Execution Services, LLC | 1,235,864 6.300% | 1,235,864 (New Position) | Filing History |
| 2025-10-31 11:05 am Purchase | 2025-09-30 | 13G | Nektar Therapeutics NKTR | VANGUARD GROUP INC | 948,647 4.980% | 948,647 (New Position) | Filing History |
| 2025-10-28 4:10 pm Sale | 2025-09-30 | 13G | Nektar Therapeutics NKTR | Integrated Core Strategies (US) LLC | 570,994 3.000% | -361,869 (-38.79%) | Filing History |
| 2025-08-14 4:45 pm Purchase | 2025-06-30 | 13G | Nektar Therapeutics NKTR | Nantahala Capital Management, LLC | 709,761 5.720% | 709,761 (New Position) | Filing History |
| 2025-08-14 4:14 pm Purchase | 2025-06-30 | 13G | Nektar Therapeutics NKTR | TCG Crossover GP II, LLC | 1,933,333 9.300% | 596,910 (+44.66%) | Filing History |
| 2025-07-18 12:10 pm Purchase | 2025-06-30 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 203,017 1.600% | 203,017 (New Position) | Filing History |
| 2025-07-09 4:39 pm Purchase | 2025-07-01 | 13G | Nektar Therapeutics NKTR | BIOTECHNOLOGY VALUE FUND L P | 1,276,595 7.400% | 1,276,595 (New Position) | Filing History |
| 2025-07-03 2:07 pm Purchase | 2025-06-27 | 13G | Nektar Therapeutics NKTR | Integrated Core Strategies (US) LLC | 932,863 5.400% | 932,863 (New Position) | Filing History |
| 2025-05-15 3:35 pm Sale | 2025-03-31 | 13G | Nektar Therapeutics NKTR | Samlyn Capital, LLC | 0 0.000% | -644,470 (Position Closed) | Filing History |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 835,200 6.700% | -229,423 (-21.55%) | Filing History |
| 2025-02-14 1:49 pm Purchase | 2024-12-31 | 13G | Nektar Therapeutics NKTR | Samlyn Capital, LLC | 644,470 5.200% | 644,470 (New Position) | Filing History |
| 2025-02-14 12:08 pm Sale | 2024-12-31 | 13G | Nektar Therapeutics NKTR | Eventide Asset Management, LLC | 443,333 3.610% | -183,333 (-29.26%) | Filing History |
| 2025-02-14 08:43 am Sale | 2024-12-31 | 13G | Nektar Therapeutics NKTR | Deep Track Capital, LP | 131,733 1.070% | -929,777 (-87.59%) | Filing History |
| 2024-11-14 12:17 pm Purchase | 2024-09-30 | 13G | Nektar Therapeutics NKTR | Eventide Asset Management, LLC | 626,667 5.110% | 626,667 (New Position) | Filing History |
| 2024-11-14 09:18 am Sale | 2024-09-30 | 13G | Nektar Therapeutics NKTR | Deep Track Capital, LP | 1,061,510 8.650% | -165,156 (-13.46%) | Filing History |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 1,064,623 8.700% | 0 (Unchanged) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Nektar Therapeutics NKTR | BlackRock Inc. BLK | 1,064,623 8.700% | 491,002 (+85.60%) | Filing History |
| 2024-03-15 4:18 pm Purchase | 2024-03-06 | 13G | Nektar Therapeutics NKTR | TCG Crossover GP II, LLC | 1,336,423 9.900% | 1,336,423 (New Position) | Filing History |